Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial Meeting Abstract
| Authors: | Gruenwald, V.; McKay, R. R.; Buchler, T.; Eto, M.; Park, S. H.; Takagi, T.; Zanetta, S.; Keizman, D.; Suarez Rodriguez, C.; Negrier, S.; Lee, J. L.; Santini, D.; Bedke, J.; Staehler, M.; Kollmannsberger, C. K.; Choueiri, T. K.; Motzer, R. J.; Burgents, J.; Okpara, C. E.; Powles, T. B. |
| Abstract Title: | Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1024 |
| End Page: | S1025 |
| Language: | English |
| ACCESSION: | WOS:001087480202567 |
| DOI: | 10.1016/j.annonc.2023.09.1133 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1903P-- Source: Wos |
